TABLE II.

Association of MBL2 genotypes on progression-free survival in children: Whole cohort

MBL2 genotypes compared	RH (95% CI), P value
O/O vs A/O*	1.45 (0.78-2.72), .24
Adjusted†	1.90 (0.94-3.85), .07
Adjusted‡	1.49 (0.78-2.84), .22
Adjusted§	1.46 (0.77-2.76), .25
O/O vs A/A*	1.29 (0.95-1.76), .10
Adjusted†	1.37 (0.97-1.94), .07
Adjusted‡	1.22 (0.89-1.67), .21
Adjusted§	1.34 (0.97-1.84), .078
O/O vs A/O+A/A*	1.57 (0.86-2.88), .14
Adjusted†	1.91 (0.97-3.76), .06
Adjusted‡	1.49 (0.80-2.75), .20
Adjusted§	1.62 (0.87-3.00), .13

^*Unadjusted.

^†Adjusted for CD4⁺ lymphocyte count, HIV-1 RNA, treatments, race, and sex.

^‡Adjusted for CCR5-wt/Δ32, -59029-G/A, CX₃CR1-249-V/I, -280-T/M, and SDF-1-180-G/A.

^§Adjusted for MBL2-H/L, MBL2-P/Q, and MBL2-X/Y.